Dr. Dan Iosifescu, MD, MSc
Claim this profileNYU Langone Health
Studies Depression
Studies Major Depressive Disorder
5 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Dan Iosifescu, MD, MSc is currently running
Transcranial Photobiomodulation
for Alzheimer's Disease
This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer's Disease (AD) (CDR of 0.5-1, FAST 1-4; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At baseline, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). After undergoing target engagement testing (t-PBM session performed during fMRI to detect BOLD changes with active t-PBM), subjects will then be randomized to t-PBM/sham and complete 24 t-PBM/sham treatments, \~11 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3).
Recruiting0 awards Phase 25 criteria
SGLT2 Inhibitor
for Depression
This trial is testing whether empagliflozin, a medication that helps produce ketone bodies, can reduce depression symptoms. It targets people with depression by providing an alternative energy source for the brain, potentially improving their mood.
Recruiting1 award Phase 23 criteria
More about Dan Iosifescu, MD, MSc
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Dan Iosifescu, MD, MSc has experience with
- Sham
- Transcranial Photobiomodulator
- Empagliflozin
- Transcranial Photobiomodulator
- Transcranial Photobiomodulation
- Aripiprazole
Breakdown of trials Dan Iosifescu, MD, MSc has run
Depression
Major Depressive Disorder
Cognitive Impairment
Mild Cognitive Impairment
Alzheimer's Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dan Iosifescu, MD, MSc specialize in?
Dan Iosifescu, MD, MSc focuses on Depression and Major Depressive Disorder. In particular, much of their work with Depression has involved treating patients, or patients who are undergoing treatment.
Is Dan Iosifescu, MD, MSc currently recruiting for clinical trials?
Yes, Dan Iosifescu, MD, MSc is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Dan Iosifescu, MD, MSc has studied deeply?
Yes, Dan Iosifescu, MD, MSc has studied treatments such as Sham, Transcranial Photobiomodulator, Empagliflozin.
What is the best way to schedule an appointment with Dan Iosifescu, MD, MSc?
Apply for one of the trials that Dan Iosifescu, MD, MSc is conducting.
What is the office address of Dan Iosifescu, MD, MSc?
The office of Dan Iosifescu, MD, MSc is located at: NYU Langone Health, New York, New York 10016 United States. This is the address for their practice at the NYU Langone Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.